RocaJunyent advises CreatSens Health on its 1M euro financing round

RocaJunyent advises the URV spin-off company Renalyse, also known as CreatSens Health, in the €1 M financing round led by the Mind the Gap II fund together with GENESIS Ventures, and with the participation of the Eurostars programme.

This significant financial injection will enable it to industrialise and certify its device for diagnosing and monitoring chronic kidney disease.

The funding received through this operation will allow Renalyse to certify its in vitro diagnostic product and reach the market in 2026. This device will be able to remotely measure three key parameters for chronic kidney disease patients, more than 90,000,000 in the European Union alone.